Form 4 for ENTA ENANTA PHARMACEUTICALS INC
Accepted 2024-06-17 00:00:00 ET · period of report 2024-06-17 · accession 0001062993-24-012734 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-06-17 | 2024-06-17 | ENTA | Kieffer Tara Lynn | Chief Product Strategy Off | S - Sale | $12.33 | -7,266 | 32.3K | -18% | -$89.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-06-17 | S | D | 7,266 | $12.33 | 32,341 | D | — | — | (F2) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $12.20 to $12.54, inclusive. |